在II期子宫内膜癌中通过长期孕激素治疗成功保持生育能力:一个病例报告
Yuki Kashihara1,2, Kentaro Sekiyama1, Akiko Abe1
1Department of Obstetrics and Gynecology, Medical Research Institute KITANO HOSPITAL, PIIF Tazuke-kofukai, Osaka, Japan.
Gynecologic oncology reports
|March 12, 2024
概括
本案例研究表明,在使用长期孕激素疗法 (美德乙) 的II期子宫内膜癌患者中,成功怀孕和活产. 这种节约生育的方法为患有晚期子宫内膜癌的妇女提供了希望.
科学领域:
- 妇科 妇科 妇科 妇科
- 生殖内分泌学 生殖内分泌学
- 在瘤学瘤学.
背景情况:
- 孕激素治疗是早期子宫内膜腺癌的公认的节育治疗方法.
- 子宫内膜腺癌,特别是II期,通常需要积极的手术干预.
研究的目的:
- 报告一个成功怀孕和活产的病例,患者患有II期子宫内膜癌,接受长期孕激素治疗.
- 为了评估甲 (MPA) 在治疗晚期子宫内膜癌的有效性,同时保持生育能力.
- 突出孕激素治疗的潜力作为一种节约生育的选择在先进子宫内膜癌的选择病例.
主要方法:
- 一名30岁的无卵子女性被诊断患有II期分化的子宫内膜癌,拒绝接受手术.
- 最初的治疗包括卵细胞冷保存,随后是孕激素治疗MPA (400毫克/天).
- 通过子宫内膜活检和成像检查监测瘤反应,随后对异型增多和最终怀孕进行重新治疗.
主要成果:
- 使用MPA的孕激素治疗导致瘤回归,并在9个月内最终消失.
- 在20个月后停止了MPA治疗,16个月后检测到非典型增生症的复发.
- 一次成功的MPA重复治疗,随后进行6个月的停药期,允许自发怀孕和分娩一个健康的婴儿.
结论:
- 长期的孕激素疗法可以成为精选患有晚期子宫内膜癌的患者有效的节育治疗方法.
- 梅德罗西孕乙酸 (MPA) 在诱导瘤回归和使随后的怀孕成为可能方面表现出显著的有效性.
- 这一案例强调了子宫内膜癌个性化治疗策略的重要性,特别是对于希望未来生育能力的年轻女性.
相关概念视频
Meiosis II
169.4K
Meiosis II is the second and final stage of meiosis. It relies on the haploid cells produced during meiosis I, each of which contain only 23 chromosomes—one from each homologous initial pair. Importantly, each chromosome in these cells is composed of two joined copies, and when these cells enter meiosis II, the goal is to separate such sister chromatids using the same microtubule-based network employed in other division processes. The result of meiosis II is two haploid cells, each...
169.4K
Ovarian Cycle
5.4K
The menstrual cycle includes a critical component known as the ovarian cycle, which undergoes two main phases each month—the follicular phase and the luteal phase. The follicular phase is variable and averaging around 14 days. Ovulation, triggered by a surge in luteinizing hormone (LH), marks the transition between the two phases. The second phase, the luteal phase, is relatively consistent, lasting approximately 14 days, and is marked by the activity of the corpus luteum. While a cycle...
5.4K


